5/29
05:45 am
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) was upgraded by analysts at Maxim Group to a "strong-buy" rating.
Medium
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) was upgraded by analysts at Maxim Group to a "strong-buy" rating.
5/17
07:06 am
cmmb
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences [Yahoo! Finance]
5/17
07:00 am
cmmb
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Medium
Report
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
5/13
09:01 am
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
Medium
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
5/10
11:58 am
cmmb
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
5/9
07:06 am
cmmb
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/9
07:00 am
cmmb
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
5/8
07:08 am
cmmb
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule [Yahoo! Finance]
High
Report
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule [Yahoo! Finance]
5/8
07:00 am
cmmb
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
High
Report
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
5/6
08:04 am
cmmb
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Medium
Report
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
5/2
07:13 am
cmmb
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference [Yahoo! Finance]
Low
Report
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference [Yahoo! Finance]
5/2
07:00 am
cmmb
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Low
Report
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
4/24
07:00 am
cmmb
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Medium
Report
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
4/18
07:23 am
cmmb
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]
High
Report
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]
4/18
07:00 am
cmmb
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
High
Report
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
4/2
07:05 am
cmmb
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]
Low
Report
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]
4/2
07:00 am
cmmb
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Low
Report
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
3/25
07:21 am
cmmb
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis [Yahoo! Finance]
Medium
Report
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis [Yahoo! Finance]
3/25
07:06 am
cmmb
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Medium
Report
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
3/7
07:03 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/7
07:00 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Medium
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
3/5
07:00 am
cmmb
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Low
Report
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference